Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications

References

• Pharmacy Quality Alliance. PQA Mission and Strategic Objectives. Available at: http://pqaalliance.org/about/default.asp [Last accessed February 2015]
   Google Scholar
• Cranston L, Dixon L. Emerging Trends in Adherence and Quality Measurement: What the Future Holds. Available at: http://www.pharmacytimes.com/publications/Directions-in-Pharmacy/2014/August2014/Emerging-Trends-in-Adherence-and-Quality-Measurement-What-the-Future-Holds [Last accessed February 2015]
   Google Scholar
• Center for Medicare & Medicaid Services. Medicare 2015 Part C & D Star Rating Technical Notes. Baltimore, MD: CMS; 2015
   Google Scholar
• Academy of Managed Care Pharmacy, American Pharmacists Association. Medicare star ratings: stakeholder proceedings on community pharmacy and managed care partnerships in quality. J Am Pharmacists Assoc 2014;54:228-40
   PubMed Web of Science ®Google Scholar
• Pharmacy Quality Alliance. Executive Update on Medication Quality Measures in Medicare Part D Plan Ratings. Springfield, VA: Pharmacy Quality Alliance; 2013
   Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar
• DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research.. Med Care 2004;42:200-209
   PubMed Web of Science ®Google Scholar
• Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation? J Thromb Haemost 2012;11:390-4
   Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Novel oral anticoagulants for atrial fibrillation. Curr Atherosclerosis Rep 2013;15:344
   PubMed Web of Science ®Google Scholar
• Aditya S. Oral and parenteral anticoagulants: new kids on the block. J Postgrad Med 2012;58:275-85
   PubMed Web of Science ®Google Scholar
• Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th Edn. Chest 2008;133(6 Suppl):160-98S
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Sardar P, Giri JS, et al. Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients. Mayo Clin Proc 2014;89:896-907
   PubMed Web of Science ®Google Scholar
• Pharmacy Quality Alliance. Performance Measures. Available at: http://pqaalliance.org/images/uploads/files/PQA measuresJuly2014.pdf [Last accessed July 2015]
   Google Scholar
• Pharmacy Quality Alliance (PQA). Technical specifications for PQA approved measures. Pharmacy Quality Alliance: Springfield, VA; 2014
   Google Scholar
• Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011;58:395-401
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100
   PubMed Web of Science ®Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010;137:263-72
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70
   PubMed Web of Science ®Google Scholar
• Nau D. Pharmacy Quality Measurement and the Connection to Accountable Care. Available at: http://www.asapnet.org/files/January2015/Presentations/ASAPJan15_Presentation03_Nau.pdf [Last accessed February 2015]
   Google Scholar
• Centers for Medicare & Medicaid Services. Medicare Health & Drug Plan Quality and Performance Ratings 2012 Part C & Part D Technical Notes. Baltimore, MD: CMS; 2012
   Google Scholar
• Centers for Medicare & Medicaid Services. Medicare 2014 Part C & D Star Rating Technical Notes. Baltimore, MD: CMS; 2014
   Google Scholar
• Di Minno A, Spadarella G, Tufano A, et al. Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs). Thrombosis Res 2014;133:699-704
   PubMed Web of Science ®Google Scholar
• Laliberté F, Pilon D, Raut MK, et al. Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 2014;30:645-53
   PubMed Web of Science ®Google Scholar
• Cowper PA, Pan W, Anstrom K, et al. Apixaban reduces hospitalization in patients with atrial fibrillation: an analysis of the effect of apixaban therapy on resource use in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. J Am Coll Cardiol 2013;61:E1576
   Web of Science ®Google Scholar
• Fonseca E, Walker DR, Hill J, et al. Dabigatran etexilate is associated with shorter hospital length of stay compared to warfarin in patients with nonvalvular atrial fibrillation. Circulation Cardiovasc Qual Outcomes 2012;5:A282
   Google Scholar
• Laliberte F, Cloutier M, Crivera C, et al. Effect of rivaroxaban vs warfarin on hospitalization days, healthcare resource utilization, and costs in nonvalvular atrial fibrillation patients using rivaroxaban. Circulation 2014;130(Suppl 2):A15809
   Google Scholar
• Adam SS, McDuffie JR, Ortel TL, et al. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 2012;157:796-807
   PubMed Web of Science ®Google Scholar
• Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40
   PubMed Web of Science ®Google Scholar
• Briesacher BA, Andrade SE, Fouayzi H, and Chan KA. Medication adherence and use of generic drug therapies. The American journal of managed care. 2009;15(7):450-456.
   Google Scholar
• Pharmaceutical Research and Manufacturers of America. Improving Prescription Medicine Adherence is Key to Better Health Care. Washington, DC: PhRMA; 2011
   Google Scholar
• Laliberté F, Nelson WW, Lefebvre P, et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012;29:675-90
   PubMed Web of Science ®Google Scholar
• Laliberté F, Bookhart BK, Nelson WW, et al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. The Patient 2013;6:213-24
   PubMedGoogle Scholar
• Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Preference and Adherence 2013;7:419-34
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm. Assessed January 2014.
   Google Scholar
• U.S. Food and Drug Administration. FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm. Assessed January 2014.
   Google Scholar
• U.S. Food and Drug Administration. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. Assessed January 2014.
   Google Scholar